Read by QxMD icon Read

Clinical Lymphoma, Myeloma & Leukemia

Courtney D DiNardo, Eytan M Stein
Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid differentiation and ultimately, to the development of AML. Inhibitors of mutant IDH1 and 2 have recently been approved by the US Food and Drug Administration and their use has led to clinical responses with prolonged duration of response. IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used...
October 21, 2018: Clinical Lymphoma, Myeloma & Leukemia
Stephen D Smith, Shruti Gandhy, Ajay K Gopal, Prathima Reddy, Mazyar Shadman, Brian G Till, Ryan C Lynch, Sandra Kanan, Andrew Cowan, Lauren Low, Brian T Hill
BACKGROUND: Initial treatment of mantle cell lymphoma (MCL) incorporating autologous stem cell transplantation affords long-term remissions, but relapses still occur. Optimal pretransplant therapy will afford high complete response rates and not impair stem cell collection. Incorporation of bortezomib represents a natural evolution of pretransplant therapy, given its proven first-line efficacy and minimal impact on stem cell collection. PATIENTS AND METHODS: At the University of Washington/Seattle Cancer Care Alliance and the Cleveland Clinic Foundation, we developed modified VR-CAP/R+ara-C (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone, alternating with rituximab and high-dose cytarabine), for transplant-eligible patients with MCL...
October 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
AnnaLynn M Williams, Andrea M Baran, Carla Casulo, Patrick Reagan, Jonathan W Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S Zent, Paul M Barr
BACKGROUND: As oral targeted agents, such as ibrutinib, become more widely used, understanding the impact of suboptimal dosing on overall survival (OS) and progression-free survival (PFS) outside of clinical trials is imperative. PATIENTS AND METHODS: Data on ibrutinib discontinuation, dose reductions, and treatment interruptions were collected on 170 non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL; n = 115, 64%) patients treated with ibrutinib at a single institution...
October 13, 2018: Clinical Lymphoma, Myeloma & Leukemia
Michael Farris, Ryan T Hughes, Zanetta Lamar, Michael H Soike, Joshua R Menke, Robert S Ohgami, Karen Winkfield
Histiocytic sarcoma (HS) is a rare aggressive malignancy with a dismal prognosis and no agreed-upon standard treatment. Classically, the diagnosis of HS has been difficult to confirm and has relied on inaccurate, crude techniques. Therapy often involves intensive chemotherapeutic regimens, surgery, and/or radiotherapy, which are poorly tolerated with variable response rates. Patients often die of diffusely metastatic disease. Modern diagnostic techniques are helping to slowly uncover more uniquely customized therapeutic approaches in this enigmatic disease...
October 13, 2018: Clinical Lymphoma, Myeloma & Leukemia
Kristine A Frerichs, Patricia W C Bosman, Inger S Nijhof, Sonja Zweegman, Niels W C J van de Donk
No abstract text is available yet for this article.
October 13, 2018: Clinical Lymphoma, Myeloma & Leukemia
Wasil Jastaniah, Mohamed Bayoumy, Abdulrahman Alsultan, Saad Al Daama, Walid Ballourah, Faisal Al-Anzi, Omar Al Shareef, Reem Al Sudairy, Mohammed Burhan Abrar, Ibrahim Al Ghemlas
BACKGROUND: The outcome of childhood acute myeloid leukemia (AML) in first relapse (rAML) remains poor. Reported overall survival (OS) rates vary between high-income developed countries and those with fewer resources. The OS of rAML in high-income developing countries (HIDCs) has not been reported. PATIENTS AND MATERIALS: A multicenter study was performed in an HIDC. The outcome of patients with relapsed non-M3/non-Down syndrome AML was evaluated. Three-year OS was computed using the Kaplan-Meier method, and predictors of OS were analyzed using a Cox proportional hazards model...
September 12, 2018: Clinical Lymphoma, Myeloma & Leukemia
Francesco Gaudio, Patrizio Mazza, Angelo Michele Carella, Anna Mele, Giulia Palazzo, Giovanni Pisapia, Paola Carluccio, Domenico Pastore, Nicola Cascavilla, Giorgina Specchia, Vincenzo Pavone
BACKGROUND: Hodgkin lymphoma (HL) is a potentially curable disease, and modern therapy is expected to successfully cure more than 80% of the patients. However, patients progressing after intensive treatments, such as autologous stem cell transplantation (SCT), have a very poor outcome. Allogeneic SCT offers the only strategy with a curative potential for these patients. This study reports a retrospective multicenter experience of the Rete Ematologica Pugliese (REP) over the past 17 years, aiming to define the impact of each patient's disease and transplant-related characteristics on outcomes...
September 12, 2018: Clinical Lymphoma, Myeloma & Leukemia
Alison K Yoder, Jillian R Gunther, Sarah A Milgrom, Dragan Mirkovic, Loretta Nastoupil, Sattva Neelapu, Michelle Fanale, Nathan Fowler, Jason Westin, Hun Ju Lee, M Alma Rodriguez, Swaminathan P Iyer, Luis Fayad, Yago L Nieto, Chitra Hosing, Sairah Ahmed, L Jeffrey Medeiros, Joseph D Khoury, Naveen Garg, Behrang Amini, Bouthaina S Dabaja, Chelsea C Pinnix
INTRODUCTION: We report successful treatment of mesenteric diffuse large B-cell lymphoma (DLBCL) using localized involved site radiation therapy (ISRT), intensity modulated radiation therapy (IMRT), and daily computed tomography (CT)-image guidance. PATIENTS AND METHODS: Patients with mesenteric DLBCL treated with RT between 2011 and 2017 were reviewed. Clinical and treatment characteristics were analyzed for an association with local control, progression-free survival (PFS), and overall survival...
September 10, 2018: Clinical Lymphoma, Myeloma & Leukemia
Ivana Horvat, Ana Boban, Renata Zadro, Margareta Radic Antolic, Ranka Serventi-Seiwerth, Pavle Roncevic, Ivo Radman, Dubravka Sertic, Marijo Vodanovic, Drazen Pulanic, Sandra Basic-Kinda, Nadira Durakovic, Silva Zupancic-Salek, Radovan Vrhovac, Igor Aurer, Damir Nemet, Boris Labar
INTRODUCTION: Thrombosis is the most common complication in Philadelphia chromosome negative (Ph-) myeloproliferative neoplasms patients. PATIENTS AND METHODS: In a cohort of 258 Ph- myeloproliferative neoplasm patients, the difference between patients with and without thrombosis was analyzed according to genetic thrombophilia factors, JAK2 V617F status and burden allele, blood count, cardiovascular risk factors and age. Patients were also divided in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) subgroups as well as by the type of thrombosis...
September 10, 2018: Clinical Lymphoma, Myeloma & Leukemia
Sikander Ailawadhi, Kevin R Kelly, Robert A Vescio, Sundar Jagannath, Jeffrey Wolf, Mecide Gharibo, Taimur Sher, Leyla Bojanini, Maurice Kirby, Asher Chanan-Khan
BACKGROUND: Despite therapeutic advancements that have significantly improved outcomes in multiple myeloma (MM), it remains an incurable disease. Patients with relapsed and/or refractory MM have an aggressive disease course, with inferior outcomes, necessitating the need for agents with novel therapeutic mechanisms. We present the results of a completed phase I trial of single-agent lorvotuzumab mertansine, a unique antibody-drug conjugate targeting CD56, which is frequently expressed in MM...
September 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
Shumaila Muhammad Iqbal, Kathryn Stecklein, Joseph Sarow, Michael Krabak, Jens Hillengass, Philip McCarthy
No abstract text is available yet for this article.
September 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
Caroline M Hsu, John M Bennett, Brea Lipe
No abstract text is available yet for this article.
September 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
Nicolas Despiégel, Chantal Touboul, Alain Flinois, Grèce Saba, Florence Suzan, Sebastian Gonzalez-McQuire, Franck Bonnetain
INTRODUCTION: New therapies for multiple myeloma (MM) have improved life expectancy, but health-related quality of life (HRQoL) data from patients with MM in the real-world setting are lacking. This study, conducted in France, explored the associations between treatment outcomes and HRQoL in patients with MM. PATIENTS AND METHODS: This observational, cross-sectional, multicenter study enrolled patients (≥ 18 years old) with symptomatic MM who had consulted a physician at least once between February and March 2016...
September 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
Xavier Leleu, Thomas G Martin, Hermann Einsele, Roger M Lyons, Brian G M Durie, Karim S Iskander, Sikander Ailawadhi
Proteasome inhibition is an established treatment strategy for patients with multiple myeloma as proteasome inhibitors (PIs) selectively target and disrupt the protein metabolism of aberrant plasma cells. Since the introduction of the first-in-class PIs bortezomib, the therapeutic landscape for multiple myeloma has shifted with the development of next-generation PIs (carfilzomib and ixazomib) and new classes of agents. Treatment with modern combination therapies has been shown to result in deep responses and improved outcomes, and these potent regimens are increasingly used as frontline therapy...
September 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
Laura Anne Habib, Kevin H M Kuo, Tony Panzarella, Vikas Gupta, Martina Trinkaus
BACKGROUND: The 2016 World Health Organization (WHO) revised classification criteria for the diagnosis of polycythemia vera (PV) allows for an earlier detection of masked PV. The literature is scarce about the clinical uptake of new diagnostic algorithms for PV. In a cohort of Canadian hematologists, we aimed to identify how the revised 2016 WHO diagnostic criteria of PV are being incorporated into hematology practice, and if the treatment of PV is comparable to the approaches outlined by the Canadian Myeloproliferative Neoplasm Group...
August 31, 2018: Clinical Lymphoma, Myeloma & Leukemia
Roberto José Pessoa de Magalhães Filho, Edvan Crusoe, Eloisa Riva, Willen Bujan, Guilhermo Conte, Juan Ramon Navarro Cabrera, Diana Katerine Garcia, Guilhermo Quintero Vega, Jose Macias, Jose Willian Oliveros Alvear, Mercedes Royg, Lidiane Andino Neves, Jose Luis Lopez Dopico, German Espino, Douglas Rosales Ortiz, Zurelis Socarra, Dorotea Fantl, Guillermo J Ruiz-Arguelles, Angelo Maiolino, Vania Tietsche de Moraes Hungria, Jean-Luc Harousseau, Brian Durie
INTRODUCTION: Latin American countries (LATAMC) represent a large fraction of patients treated for multiple myeloma (MM) worldwide. In order to understand the difficulty of access to anti-myeloma therapy in LATAMC, we designed this study that explores areas involved in the availability of drugs, such as health care systems, approval times, coverage of new agents, old drugs, use of generics, and the first-line treatments. MATERIAL AND METHODS: We collected data from 16 countries in 2015...
August 29, 2018: Clinical Lymphoma, Myeloma & Leukemia
Moussab Damlaj, Mohsen Al-Zahrani, Ghulam Syed, Giamal Gmati, Bader Alahmari, Tabrez Pasha, Ayman Alhejazi, Ahmed Alaskar
BACKGROUND: Response-adapted therapy in advanced classical Hodgkin lymphoma (cHL) using interim functional imaging (IFI) is under active investigation. PATIENTS AND METHODS: We retrospectively examined patients with advanced cHL receiving 2 front-line regimens stratified by IFI results at our institution. Time to endpoint analysis was estimated using the method of Kaplan-Meier with log ranks. Cox regression modeling was computed for multivariable analysis. RESULTS: A total of 124 patients with advanced cHL with a median follow up of 40...
August 29, 2018: Clinical Lymphoma, Myeloma & Leukemia
Yoo Jin Lee, Dong Won Baek, Jae-Sook Ahn, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Hyeoung Joon Kim, Ji Yeon Ham, Jang Soo Suh, Sang Kyun Sohn, Joon Ho Moon
BACKGROUND: The optimal number of high-dose cytarabine (HDAC) consolidation cycles before allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia is not fully standardized. PATIENTS AND METHODS: This study evaluated the impact of HDAC consolidation cycles before allogeneic HCT in 194 patients with acute myeloid leukemia in first complete remission between 1998 and 2014. The patients were reclassified into 3 groups-no consolidation (C0, n = 20), 1 consolidation (C1, n = 115), and ≥ 2 consolidations (C2, n = 59)-by pre-HCT consolidation cycle...
August 29, 2018: Clinical Lymphoma, Myeloma & Leukemia
Rachel J David, Andrea Baran, Kah Poh Loh, Carla Casulo, Paul M Barr, Jonathan W Friedberg, Patrick M Reagan
INTRODUCTION: Certain aggressive non-Hodgkin lymphoma subtypes are increasingly being treated with infusional DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), which requires a central venous catheter. This study aims to identify the rates and predictors of line-associated complications (LACs) associated with DA-EPOCH-R therapy in NHL. PATIENTS AND METHODS: We retrospectively identified all patients treated with DA-EPOCH-R at our institution between March 2011 and July 2016...
August 29, 2018: Clinical Lymphoma, Myeloma & Leukemia
Michael R Grunwald, Brady L Stein, Ralph V Boccia, Stephen T Oh, Dilan Paranagama, Shreekant Parasuraman, Philomena Colucci, Ruben Mesa
BACKGROUND: Polycythemia vera (PV) has a prevalence of 44 to 57 per 100,000 people in the United States. Prospective data concerning the demographics, clinical characteristics, and treatment patterns of patients with PV in the United States are lacking. PATIENTS AND METHODS: The ongoing, prospective, observational REVEAL study evaluates demographics, disease burden, clinical management, patient-reported outcomes, and health care resource utilization of adult patients with PV in the United States...
August 29, 2018: Clinical Lymphoma, Myeloma & Leukemia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"